Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED

大成生化科技集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00809)

SUPPLIERS DEBT RESTRUCTURING ARRANGEMENT INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement (the "**Announcement**") of Global Bio-chem Technology Group Company Limited (the "**Company**") dated 8 July 2025 in relation to the Suppliers Debt Restructuring Arrangement involving the issue of Consideration Shares under Specific Mandate and the announcement of the Company dated 31 July 2025 (the "**Delay Announcement**"). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Delay Announcement, a circular (the "**Circular**") containing, among others, (i) further information of the SPAs and the transactions contemplated thereunder, including the Re-acquisition and the grant of the Specific Mandate for the issue of the Consideration Shares; (ii) a notice of the EGM; and (iii) other information as required to be disclosed under the Listing Rules, was expected to be despatched to the Shareholders on or before 22 August 2025.

As additional time is required to prepare and finalise certain information to be included in the Circular, it is expected that the Circular will be despatched on or before 5 September 2025.

By order of the Board
Global Bio-chem Technology Group Company Limited
Wang Cheng
Chairman

Hong Kong, 21 August 2025

As of the date of this announcement, the Board comprises two executive Directors, namely, Mr. Wang Cheng and Mr. Wang Guicheng; one non-executive Director, namely, Mr. Li Yuewen; and three independent non-executive Directors, namely, Ms. Jiang Fangfang, Mr. Tan Chao and Ms. Xie Liangqiu.

** For identification purposes only*